Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo: Enhanced gene transfer and adjuvant activity.

abstract：:The prostaglandin (PG) synthetase cyclooxygenase 2 (Cox-2) promotes tumorigenesis, tumor progression, and metastasis in a variety of human cancer entities including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrate that in PDAC cells such as Colo357 cells, enhanced Cox-2 expression and increased r...

journal_title：Oncoimmunology

authors： Gonnermann D,Oberg HH,Kellner C,Peipp M,Sebens S,Kabelitz D,Wesch D

更新日期：2015-01-07 00:00:00

abstract：:Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called "maturation cocktail" ...

journal_title：Oncoimmunology

authors： Garg AD,Vara Perez M,Schaaf M,Agostinis P,Zitvogel L,Kroemer G,Galluzzi L

更新日期：2017-05-12 00:00:00

abstract：:Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...

journal_title：Oncoimmunology

authors： Choi JH,Kim KH,Roh KH,Jung H,Lee A,Lee JY,Song JY,Park SJ,Kim I,Lee WS,Seo SK,Choi IW,Fu YX,Yea SS,Park S

更新日期：2018-01-16 00:00:00

abstract：:Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

journal_title：Oncoimmunology

authors： Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

更新日期：2014-01-01 00:00:00

abstract：:Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

journal_title：Oncoimmunology

authors： Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

更新日期：2014-01-01 00:00:00

abstract：:Interleukin-10 (IL-10) is a potent immunomodulatory cytokine, whose cellular targets have not yet been precisely identified. Dendritic cell (DC)-specific IL-10 receptor knockout mice exhibit exaggerated T-cell reactivation in the skin, highlighting a key role of DCs in the maintenance of local immune homeostasis, beyo...

journal_title：Oncoimmunology

authors： Clausen BE,Girard-Madoux MJ

更新日期：2013-03-01 00:00:00

abstract：:PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8α(+)) have sensors for dsRNA including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 a...

journal_title：Oncoimmunology

authors： Azuma M,Ebihara T,Oshiumi H,Matsumoto M,Seya T

更新日期：2012-08-01 00:00:00

abstract：:Toll-like receptor 9 (TLR9) is a cellular DNA-receptor of the innate immune system that is widely expressed in cancers. We demonstrated that low tumor TLR9 expression predicts poor disease-specific survival in triple negative breast cancer (TNBC) and renal cell carcinoma (RCC). We hypothesized that this is because TLR...

journal_title：Oncoimmunology

authors： Mella M,Kauppila JH,Karihtala P,Lehenkari P,Jukkola-Vuorinen A,Soini Y,Auvinen P,Vaarala MH,Ronkainen H,Kauppila S,Haapasaari KM,Vuopala KS,Selander KS

更新日期：2015-05-22 00:00:00

abstract：:Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20-40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this regard, a handful of ...

journal_title：Oncoimmunology

authors： Bauzon M,Drake PM,Barfield RM,Cornali BM,Rupniewski I,Rabuka D

更新日期：2019-01-22 00:00:00

abstract：:Lung-specific overexpression of prostacyclin synthase (PGIS) decreases tumor initiation in murine lung cancer models. Prostacyclin analogs prevent lung tumor formation in mice and reverse bronchial dysplasia in former smokers. However, the effect of prostacyclin on lung cancer progression has not been well studied. We...

journal_title：Oncoimmunology

authors： Li HY,McSharry M,Walker D,Johnson A,Kwak J,Bullock B,Neuwelt A,Poczobutt JM,Sippel TR,Keith RL,Weiser-Evans MCM,Clambey E,Nemenoff RA

更新日期：2018-02-13 00:00:00

abstract：:Removal of immuno-suppression has been reported to enhance antitumor immunity primed by checkpoint inhibitors. Although PD-1 blockade failed to control tumor growth in a transgenic murine neuroblastoma model, concurrent inhibition of colony stimulating factor 1 receptor (CSF-1R) by BLZ945 reprogrammed suppressive myel...

journal_title：Oncoimmunology

authors： Eissler N,Mao Y,Brodin D,Reuterswärd P,Andersson Svahn H,Johnsen JI,Kiessling R,Kogner P

更新日期：2016-09-09 00:00:00

abstract：:Interleukin (IL)-17A belongs to IL-17 superfamily and binds the heterodimeric IL-17 receptor (R)(IL-17RA/IL-17RC). IL-17A promotes germinal center (GC) formation in mouse models of autoimmune or infectious diseases, but the role of IL-17A/IL-17AR complex in human neoplastic GC is unknown. In this study, we investigate...

journal_title：Oncoimmunology

authors： Ferretti E,Di Carlo E,Ognio E,Guarnotta C,Bertoni F,Corcione A,Prigione I,Fraternali-Orcioni G,Ribatti D,Ravetti JL,Ponzoni M,Tripodo C,Pistoia V

更新日期：2015-06-19 00:00:00

abstract：:A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immunomodulatory agents ...

journal_title：Oncoimmunology

authors： Hardwick N,Chung V,Cristea M,Ellenhorn JD,Diamond DJ

更新日期：2014-12-15 00:00:00

abstract：:Immune check point inhibitors targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1) have shown clinical success in treatment of human malignancies. Triple negative breast cancer (TNBC), which is primarily characterized by high heterogeneity and presence of tumor infiltrating lymphocytes, remains ther...

journal_title：Oncoimmunology

authors： Mohan N,Hosain S,Zhao J,Shen Y,Luo X,Jiang J,Endo Y,Wu WJ

更新日期：2019-06-06 00:00:00

abstract：:The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunity requires FPR1 and...

journal_title：Oncoimmunology

authors： Baracco EE,Pietrocola F,Buqué A,Bloy N,Senovilla L,Zitvogel L,Vacchelli E,Kroemer G

更新日期：2016-02-18 00:00:00

abstract：: Background : Peritoneal carcinomatosis (PC) is a terminal evolution from primary colorectal cancer (pCRC) associated with poor patient survival. Impact of the immune cell infiltrate on PC pathogenesis is unknown. Therefore, we characterized the immunological tumor microenv...

journal_title：Oncoimmunology

authors： Seebauer CT,Brunner S,Glockzin G,Piso P,Ruemmele P,Schlitt HJ,Geissler EK,Fichtner-Feigl S,Kesselring R

更新日期：2016-10-14 00:00:00

abstract：:Although high levels of tumor-infiltrating lymphocytes (TILs) generally correlate with good prognosis in high-grade serous ovarian cancer (HGSC) patients, little is known about the phenotype or specificity of these cells. We have recently demonstrated that TIL expressing the intra-epithelial lymphocyte marker CD103 (o...

journal_title：Oncoimmunology

authors： Webb JR,Milne K,Nelson BH

更新日期：2014-01-10 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 for detecting BRAF V...

journal_title：Oncoimmunology

authors： Zeng K,Wang Z,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Y,Yu Z,Yan Q,Guo S,Wei J,Guo Y

更新日期：2016-06-14 00:00:00

abstract：:Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain and those with nei...

journal_title：Oncoimmunology

authors： Fisher J,Kramer AM,Gustafsson K,Anderson J

更新日期：2014-12-23 00:00:00

abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

journal_title：Oncoimmunology

authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

更新日期：2015-01-30 00:00:00

abstract：:Somatic gain-of-function mutations in isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) or isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) are bona fide oncogenic drivers of acute myeloid leukemia and glioma because the neomorphic enzymes catalyze the synthesis of R-2-hydroxylutarate (R-2-HG), an oncom...

journal_title：Oncoimmunology

authors： Galluzzi L,Kroemer G

更新日期：2018-10-16 00:00:00

abstract：:Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical t...

journal_title：Oncoimmunology

authors： Wainwright DA,Lesniak MS

更新日期：2014-05-15 00:00:00

abstract：:Natural killer (NK)-cell count is predictive of chronic lymphoid leukemia (CLL) disease progression and their dysfunction is well documented, but the etiology of this is currently lacking. CLL cells have been shown to over-express HLA-E, the natural ligand for NKG2A expressed on NK-cells that generates a distinct nega...

journal_title：Oncoimmunology

authors： McWilliams EM,Mele JM,Cheney C,Timmerman EA,Fiazuddin F,Strattan EJ,Mo X,Byrd JC,Muthusamy N,Awan FT

更新日期：2016-09-09 00:00:00

abstract：:CD69 is an early activation marker on the surface of T lymphocytes undergoing activation by cognate antigen. We observed intense expression of CD69 on tumor-infiltrating T-lymphocytes that reside in the hypoxic tumor microenvironment and hypothesized that CD69 could be, at least partially, under the control of the tra...

journal_title：Oncoimmunology

authors： Labiano S,Meléndez-Rodríguez F,Palazón A,Teijeira Á,Garasa S,Etxeberria I,Aznar MÁ,Sánchez-Paulete AR,Azpilikueta A,Bolaños E,Molina C,de la Fuente H,Maiso P,Sánchez-Madrid F,de Landázuri MO,Aragonés J,Melero I

更新日期：2017-01-19 00:00:00

abstract：:Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first intravesical applica...

journal_title：Oncoimmunology

authors： Rentsch CA,Bosshard P,Mayor G,Rieken M,Püschel H,Wirth G,Cathomas R,Parzmair GP,Grode L,Eisele B,Sharma H,Gupta M,Gairola S,Shaligram U,Goldenberger D,Spertini F,Audran R,Enoiu M,Berardi S,Hayoz S,Wicki A

更新日期：2020-04-21 00:00:00

abstract：:Tumor-associated macrophages play a central role in tumor progression and metastasis. Macrophages can also promote the resistance of malignant cells to chemotherapy by stimulating the upregulation of cytidine deaminase, an intracellular enzyme that catabolizes the active form of gemcitabine. Targeting macrophage-depen...

journal_title：Oncoimmunology

authors： Amit M,Gil Z

更新日期：2013-12-01 00:00:00

abstract：:MDR1 is an ATP-dependent transmembrane transporter primarily studied for its role in the detoxification of tissues and for its implication in resistance of tumor cells to chemotherapy treatment. Several studies also report on its expression on immune cells where it plays a protective role from xenobiotics and toxins. ...

journal_title：Oncoimmunology

authors： Bossennec M,Di Roio A,Caux C,Ménétrier-Caux C

更新日期：2018-09-06 00:00:00

abstract：:The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression. However, separation of TEX from non-TEX in patients' plasma requires tumor antigen-specific detection reagents. CD44v3 has been of interest as...

journal_title：Oncoimmunology

authors： Theodoraki MN,Matsumoto A,Beccard I,Hoffmann TK,Whiteside TL

更新日期：2020-04-07 00:00:00

abstract：:Recently, the study of microRNAs has expanded our knowledge of the fundamental processes of cancer biology and the underlying mechanisms behind tumor metastasis. Extensive research in the fields of microRNA and its novel mechanisms of actions against various cancers has more recently led to the trial of a first cancer...

journal_title：Oncoimmunology

authors： Park JH,Theodoratou E,Calin GA,Shin JI

更新日期：2016-09-09 00:00:00

abstract：:We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the divers...

journal_title：Oncoimmunology

authors： Omokoko T,Simon P,Türeci Ö,Sahin U

更新日期：2015-03-19 00:00:00